EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study

Leopoldo Pérez de Isla iD, Jose L Díaz-Díaz iD, Manuel J Romero iD, Ovidio Muñiz-Grijalvo iD, Juan D Mediavilla, Rosa Argüeso, Juan F Sánchez Muñoz-Torrero, Patricia Rubio iD, Pilar Álvarez-Baños, Paola Ponte iD, Dolores Mañas, Lorena Suárez Gutierrez iD und 9 weitere

Circulation · 09.05.2023 · 147 (19) · 1436-1443

DOI: 10.1161/circulationaha.122.062557 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Circulation, erschienen am 09.05.2023. Verfasst von Leopoldo Pérez de Isla und 20 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, Clinico San Carlos University Hospital, Madrid, Spain (L.P.d.I.). Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Coronary Artery Disease, Hypercholesterolemia, Plaque, Atherosclerotic. Die Arbeit wurde bisher 90-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The effect of alirocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, on coronary plaque burden in patients with familial hypercholesterolemia has not been addressed. Our aim was to assess changes in coronary plaque burden and its characteristics after treatment with alirocumab by quantification and characterization of atherosclerotic plaque throughout the coronary tree on the basis of a noninvasive analysis of coronary computed tomographic angiography in asymptomatic subjects with familial hypercholesterolemia receiving optimized and stable treatment with maximum tolerated statin dose with or without ezetimibe.

Methods

This study is a phase IV, open-label, multicenter, single-arm clinical trial to assess changes in coronary plaque burden and its characteristics after 78 weeks of treatment with alirocumab in patients with familial hypercholesterolemia without clinical atherosclerotic cardiovascular disease. Participants underwent an initial coronary computed tomographic angiography at baseline and another at 78 weeks. Every patient received 150 mg of alirocumab subcutaneiously every 14 days in addition to high-intensity statin therapy. The main outcome was the change on coronary plaque burden and its characteristics by quantification and characterization of atherosclerotic plaque throughout the coronary tree on the basis of analysis of coronary computed tomographic angiography.

Results

The study was completed by 104 patients. The median age was 53.3 (46.2–59.4) years. Of these patients, 54 were women (51.9%). Median low-density lipoprotein cholesterol was 138.9 (117.5–175.3) mg/dL at entry and 45.0 (36.0–65.0) mg/dL at follow-up ( P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsCoronary Artery DiseaseHypercholesterolemiaPlaque, AtheroscleroticHyperlipoproteinemia Type IIAtherosclerosisAcute Coronary SyndromeHumansFemaleMiddle AgedMaleProprotein Convertase 9Treatment OutcomeAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

alirocumabcomputed tomography angiographycoronary artery diseasehypercholesterolemiaplaque, atherosclerotic

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9alirocumabAntibodies, Monoclonal, HumanizedPCSK9 protein, human

Autor:innen und Institutionen

  • Cardiology Department, Clinico San Carlos University Hospital, Madrid, Spain (L.P.d.I.).
  • Internal Medicine Department, Hospital Abente y Lago, A Coruña, Spain (J.L.E.-D.).
  • Internal Medicine Department, Hospital Infanta Elena, Huelva, Spain M.J.R.).
  • Internal Medicine Department, Hospital Virgen del Rocío, Sevilla, Spain (O.M.-G.).
  • Internal Medicine Department, Hospital Universitario Virgen de las Nieves, Granada, Spain (J.D.M.).
  • Endocrinology Department, Hospital Universitario Lucus Augusti, Lugo, Spain (R.A.).

ORCID-Profile: Leopoldo Pérez de Isla, Jose L Díaz-Díaz, Manuel J Romero, Ovidio Muñiz-Grijalvo, Patricia Rubio, Paola Ponte, Lorena Suárez Gutierrez, Francisco Fuentes, Carlos Guijarro, Miguel Ángel Barba, Teresa Padró

Zitieren

APA

Pérez de Isla, L., Díaz-Díaz, J. L., Romero, M. J., Muñiz-Grijalvo, O., Mediavilla, J. D., Argüeso, R., Sánchez Muñoz-Torrero, J. F., Rubio, P., Álvarez-Baños, P., Ponte, P., Mañas, D., Suárez Gutierrez, L., Cepeda, J. M., Casañas, M., Fuentes, F., Guijarro, C., Ángel Barba, M., Saltijeral Cerezo, A., Padró, T., …, & SAFEHEART Study Group (2023). Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study. Circulation, 147(19), 1436-1443. https://doi.org/10.1161/circulationaha.122.062557

Vancouver

Pérez de Isla L, Díaz-Díaz JL, Romero MJ, Muñiz-Grijalvo O, Mediavilla JD, Argüeso R, et al. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study. Circulation. 2023;147(19):1436-1443. doi:10.1161/circulationaha.122.062557

BibTeX
@article{PrezdeIsla2023,
  author = {Pérez de Isla, Leopoldo and Díaz-Díaz, Jose L and Romero, Manuel J and Muñiz-Grijalvo, Ovidio and Mediavilla, Juan D and Argüeso, Rosa and Sánchez Muñoz-Torrero, Juan F and Rubio, Patricia and Álvarez-Baños, Pilar and Ponte, Paola and Mañas, Dolores and Suárez Gutierrez, Lorena and Cepeda, José María and Casañas, Marta and Fuentes, Francisco and Guijarro, Carlos and Ángel Barba, Miguel and Saltijeral Cerezo, Adriana and Padró, Teresa and Mata, Pedro and SAFEHEART Study Group, SAFEHEART Study Group},
  title = {Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study},
  journal = {Circulation},
  year = {2023},
  volume = {147},
  number = {19},
  pages = {1436--1443},
  doi = {10.1161/circulationaha.122.062557}
}
Kostenlos starten →